Treatment Patterns for End-Stage Kidney Failure in Patients With Systemic Lupus Erythematous.

IF 2.4 4区 医学 Q2 RHEUMATOLOGY
JCR: Journal of Clinical Rheumatology Pub Date : 2024-08-01 Epub Date: 2024-05-16 DOI:10.1097/RHU.0000000000002088
Chunhuan Lao, Philippa Van Dantzig, Kannaiyan Rabindranath, Douglas White, Ross Lawrenson
{"title":"Treatment Patterns for End-Stage Kidney Failure in Patients With Systemic Lupus Erythematous.","authors":"Chunhuan Lao, Philippa Van Dantzig, Kannaiyan Rabindranath, Douglas White, Ross Lawrenson","doi":"10.1097/RHU.0000000000002088","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aims to examine the treatment patterns of end-stage kidney disease (ESKD) among SLE patients and to compare the outcome of hemodialysis (HD) and peritoneal dialysis (PD).</p><p><strong>Methods: </strong>SLE patients identified from the national administration dataset in 2005-2021 were linked to the Australia and New Zealand Dialysis and Transplant Registry to identify ESKD cases. The adjusted odds ratio of having PD instead of HD as the first treatment for ESKD for Asian, Māori, and Pacific compared with European/others was estimated with the logistic regression model. The adjusted hazards ratio of all-cause mortality for patients having PD first compared with HD first was calculated.</p><p><strong>Results: </strong>Two hundred ten ESKD patients with SLE were identified. Two thirds (137/210) of the ESKD patients had HD as the first treatment, and one third (68, 32.4%) had PD first. Around 60% of Asian patients had PD as the first treatment, compared with 30% in other ethnic groups. The adjusted odds ratio of having PD as the first treatment for Asian patients compared with European/others was 3.00 (95% confidence interval, 1.16-7.73). The adjusted hazards ratio of all-cause mortality for patients in the PD group compared with the HD group was 0.60 (95% confidence interval, 0.37-0.97).</p><p><strong>Conclusions: </strong>Asian patients with ESKD were more likely to have PD as the first treatment. The optimal dialysis type for ESKD patients with SLE might be different from ESKD patients caused by other diseases. ESKD patients with SLE receiving PD first had superior outcomes than patients receiving HD first.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":"183-187"},"PeriodicalIF":2.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCR: Journal of Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RHU.0000000000002088","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This study aims to examine the treatment patterns of end-stage kidney disease (ESKD) among SLE patients and to compare the outcome of hemodialysis (HD) and peritoneal dialysis (PD).

Methods: SLE patients identified from the national administration dataset in 2005-2021 were linked to the Australia and New Zealand Dialysis and Transplant Registry to identify ESKD cases. The adjusted odds ratio of having PD instead of HD as the first treatment for ESKD for Asian, Māori, and Pacific compared with European/others was estimated with the logistic regression model. The adjusted hazards ratio of all-cause mortality for patients having PD first compared with HD first was calculated.

Results: Two hundred ten ESKD patients with SLE were identified. Two thirds (137/210) of the ESKD patients had HD as the first treatment, and one third (68, 32.4%) had PD first. Around 60% of Asian patients had PD as the first treatment, compared with 30% in other ethnic groups. The adjusted odds ratio of having PD as the first treatment for Asian patients compared with European/others was 3.00 (95% confidence interval, 1.16-7.73). The adjusted hazards ratio of all-cause mortality for patients in the PD group compared with the HD group was 0.60 (95% confidence interval, 0.37-0.97).

Conclusions: Asian patients with ESKD were more likely to have PD as the first treatment. The optimal dialysis type for ESKD patients with SLE might be different from ESKD patients caused by other diseases. ESKD patients with SLE receiving PD first had superior outcomes than patients receiving HD first.

系统性红斑狼疮患者终末期肾衰竭的治疗模式。
背景:本研究旨在探讨系统性红斑狼疮患者终末期肾病(ESKD)的治疗模式,并比较血液透析(HD)和腹膜透析(PD)的疗效:方法:将2005-2021年从国家管理数据集中确认的系统性红斑狼疮患者与澳大利亚和新西兰透析与移植登记处进行链接,以确认ESKD病例。采用逻辑回归模型估算了亚裔、毛利人和太平洋岛屿族裔与欧裔/其他族裔相比,在ESKD的首次治疗中使用透析而非HD的调整后几率。结果显示,有210名ESKD患者在首次治疗时选择了PD,而不是HD:结果:共发现 210 名患有系统性红斑狼疮的 ESKD 患者。三分之二(137/210)的 ESKD 患者首先接受了 HD 治疗,三分之一(68,32.4%)的患者首先接受了 PD 治疗。约60%的亚裔患者首先接受了PD治疗,而其他族裔群体的这一比例为30%。亚裔患者与欧裔/其他族裔患者相比,将腹膜透析作为首选治疗方法的调整后几率比为 3.00(95% 置信区间,1.16-7.73)。与 HD 组相比,PD 组患者全因死亡率的调整后危险比为 0.60(95% 置信区间,0.37-0.97):结论:ESKD亚裔患者更有可能将PD作为首选治疗方法。患有系统性红斑狼疮的 ESKD 患者的最佳透析类型可能与其他疾病引起的 ESKD 患者不同。首先接受透析治疗的系统性红斑狼疮 ESKD 患者的疗效优于首先接受 HD 治疗的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
2.90%
发文量
228
审稿时长
4-8 weeks
期刊介绍: JCR: Journal of Clinical Rheumatology the peer-reviewed, bimonthly journal that rheumatologists asked for. Each issue contains practical information on patient care in a clinically oriented, easy-to-read format. Our commitment is to timely, relevant coverage of the topics and issues shaping current practice. We pack each issue with original articles, case reports, reviews, brief reports, expert commentary, letters to the editor, and more. This is where you''ll find the answers to tough patient management issues as well as the latest information about technological advances affecting your practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信